Advertisement

Organisation › Details
BenevolentAI (Group)
At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company’s business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, advancing in-house pipelines to inflection points, and commercialising a suite of knowledge exploration tools. Headquartered in London, with wet labs in Cambridge (UK) and an office in New York, BenevolentAI is at the forefront of reshaping the future of drug discovery and delivering innovative medicines. *
![]() |
Start | 2013-01-01 established |
![]() |
Industry | artificial intelligence (AI) / machine learning (ML) |
Industry 2 | LIFE SCIENCES | |
![]() |
Person | Möller, Jörg (BenevolentAI 202401– CEO before Leo Pharma + Bayer 201403–202012) |
Person 2 | Isted, Catherine (BenevolentAI 202309– CFO before ReNeuron + Oxford Biomedica + Morgan Stanley + ABN AMRO + Nomura) | |
![]() |
Region | London, Greater London |
Country | United Kingdom (GB) | |
Street | 4–8 Maple Street | |
City | W1T 5HD London | |
Tel | +44-20-37819-360 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | D: 101 to 500 (2023-12-31) |
Currency | GBP | |
Annual sales | 191,000 (operating income, other (2023) 2023-12-31) | |
Profit | -317,528,000 (2023-12-31) | |
Cash | 4,597,000 (2023-12-31) | |
* Document for »About Section«: BenevolentAI Ltd.. (1/24/24). "Press Release: BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer". London. | ||
Record changed: 2024-06-05 |
Advertisement

More documents for BenevolentAI (Group)
- [1] BenevolentAI Ltd.. (12/11/24). "Press Release: BenevolentAI Unveils Major Strategic Overhaul with Return to Original Mission". London....
- [2] BenevolentAI Ltd.. (10/17/24). "Press Release: BenevolentAI Appoints Kenneth Mulvany as Executive Chairman". London....
- [3] BenevolentAI S.A.. (6/4/24). "Press Release: BenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference"....
- [4] BenevolentAI Ltd.. (1/24/24). "Press Release: BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer". London....
- [5] BenevolentAI. (9/20/23). "Press Release: BenevolentAI Signs Strategic Collaboration with Merck". London....
- [6] BenevolentAI. (9/18/23). "Press Release: BenevolentAI Welcomes Christina Busmalis as Its New Chief Revenue Officer". London....
- [7] BenevolentAI. (9/11/23). "Press Release: Appointment of Catherine Isted, ACMA, as Chief Financial Officer". London....
- [8] BenevolentAI. (5/25/23). "Press Release: BenevolentAI Unveils Strategic Plan to Position the Company for a New Era in AI". London....
- [9] Euronext N.V.. (4/25/22). "Press Release: BenevolentAI Lists on Euronext Amsterdam. Listed Following Business Combination with Odyssey Acquisition S.A.". Amsterdam....
- [10] BenevolentAI. (4/25/22). "Press Release: BenevolentAI Begins Trading On Euronext Amsterdam". London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top